# Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Source: https://onco.cc/trials/nct04728893/  
OnCo record `nct04728893` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nemtabrutinib in chronic lymphocytic leukaemia, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) is a phase 2 interventional study registered as NCT04728893 by Merck Sharp & Dohme LLC, with 490 participants planned, started 2021-04-05 and due to reach its primary completion in 2029-01-04. Interventions recorded: Nemtabrutinib. Conditions listed: Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04728893
- Phase: 2
- Setting: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 490

## Sources

- ClinicalTrials.gov NCT04728893: https://clinicaltrials.gov/study/NCT04728893

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Nemtabrutinib](https://onco.cc/drugs/nemtabrutinib/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04728893.json